Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma.
D007516:Adenoma, Islet Cell / Q000188:drug therapy / Q000503:physiopathology*; D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose; D003981:Diazoxide / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D005951:Glucose Tolerance Test; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D010672:Phenytoin / Q000627:therapeutic use*; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy / Q000503:physiopathology*
D001786:Blood Glucose; D007328:Insulin; D010672:Phenytoin; D005947:Glucose; D003981:Diazoxide